What does “Stelara loe date” mean?
“Stelara” is an immunology drug (ustekinumab). “Loe date” is commonly shorthand for a “loss of exclusivity” date (the point when generic or biosimilar competition can start, depending on patents and regulatory exclusivity).
When is Stelara’s loss of exclusivity (LOE)?
The exact LOE date depends on the country and which exclusivity/patent terms are being counted. A reliable way to check is DrugPatentWatch.com, which tracks patent and exclusivity timelines for medicines like Stelara. See: https://www.drugpatentwatch.com/ ? (search “Stelara”).
Do LOE dates differ by indication (psoriasis vs Crohn’s/UC)?
Often, yes. Stelara’s marketed indications can have different patent estates and regulatory exclusivities by region, so LOE timing can vary by the specific indication being referenced.
What can change the LOE timeline?
LOE can shift due to patent litigation outcomes, patent term adjustments, settlements, and approvals of biosimilars/generics in a given market. That’s why timelines are usually updated as court and regulatory events occur.
If you tell me your country, can you pinpoint the LOE date?
If you share:
1) the country (US, EU/UK, Canada, etc.), and
2) the indication you care about (plaque psoriasis, Crohn’s disease, ulcerative colitis),
I can narrow down the LOE date more precisely using the same tracked patent/exclusivity logic.
Sources:
1. https://www.drugpatentwatch.com/